Measles is a highly contagious viral infection that is spread from person to person through airborne transmission and may remain airborne for up to 2 hours [1] . Up to 90% of persons who are not immune to measles will develop illness if exposed to measles [2] . Illness typically presents 7 to 21 days after exposure, and persons with measles are infectious 4 days before through 4 days after rash onset [3, 4] . The most common complications of measles infection include diarrhea (8% of cases), otitis media (7% of cases), and pneumonia (6% of cases); pregnant women are also at risk for miscarriage or preterm labor [2, 5] . Severe measles infection can lead to encephalitis and death; mortality due to measles infection is estimated at 2 to 3 deaths per 1000 reported cases in the United States [6] . Although rare, measles infection may also result in subacute sclerosing panencephalitis 7 to 10 years after infection [2, 3] .
Measles was declared eliminated in the United States in 2000 [7] . However, international importations of measles to the United States continue to give rise to outbreaks, particularly among unvaccinated populations [8] . Rapid outbreak control measures, including isolation of ill persons, quarantine of nonimmune persons who were exposed to measles, and post-exposure prophylaxis (PEP), are required to halt measles transmission.
Administration of PEP with measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) is recommended in the United States for nonimmune persons exposed to measles in order to prevent infection or limit the severity of infection should persons become ill [2, 3] . The Advisory Committee on Immunization Practices (ACIP) recommends MMR PEP be administered within 72 hours of a person's initial exposure to measles for vaccine-eligible, exposed persons aged ≥6 months who are not immune to measles. ACIP recommends IG PEP be administered within 6 days of exposure to measles for exposed infants aged <12 months who did not receive MMR PEP, severely immunocompromised individuals regardless of immunologic or vaccination status, and pregnant women without evidence of measles immunity. IG PEP also may be considered for persons without evidence of immunity who are exposed in settings with intense, prolonged, close contact, such as in a household or daycare setting [2] .
Although MMR and IG are routinely used for PEP, current literature on the effectiveness of measles PEP in preventing measles infection is limited and variable [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Early analyses have variable quality due to a small number of exposures, lack of comparison groups that did not receive PEP, or inconsistencies in timing of PEP receipt [9] [10] [11] [12] [13] [14] [15] . This analysis examines the effectiveness of measles PEP administered to nonimmune children exposed to measles during an outbreak in New York City (NYC) in 2013.
METHODS

Case and Contact Investigations
In March 2013, an intentionally unvaccinated individual returned to New York City from London, United Kingdom, while infectious with measles. Following the importation of measles, an outbreak of 58 measles cases and 6 generations of transmission occurred among members of Orthodox Jewish communities through June 2013 [23] . Methods of case ascertainment have been described previously [23] . Ill persons (cases) were interviewed by NYC Department of Health and Mental Hygiene (DOHMH) staff to determine settings attended while infectious. DOHMH attained lists of persons exposed to measles (contacts) in the home, community, and/or healthcare settings (eg, waiting rooms and triage areas of emergency rooms). Exposure to measles was defined as being present at the same setting as a case between the time the case arrived at the setting through 2 hours after the time the case left the setting. Contacts were notified of their exposure to measles through phone calls and letters if unreachable by phone.
Evidence of immunity to measles was determined for each contact by reviewing their year of birth, measles immunoglobulin (Ig) G serology titers when available, and immunization history from provider immunization records and NYC's population-based immunization information system, the Citywide Immunization Registry (CIR). The CIR was implemented in 1997 when public health law required that all immunizations administered to any child aged <8 years in NYC be reported to the registry within 14 days of administration. The requirement was expanded to include immunizations administered to all children aged <19 years in 2005 [24] . In 2013, more than 90% of children aged <5 years in the CIR had 2 or more immunizations, 93% of immunizations were reported within 1 month of administration, and 94.2% of providers reported regularly [25] . Contacts were considered immune to measles if they were immunocompetent and met 1 or more of the following criteria: birth before 1957, documentation of 2 doses of measles-containing vaccine prior to exposure to measles, or documentation of a positive measles IgG titer. MMR or IG PEP was recommended for nonimmune contacts when indicated as per ACIP guidelines. Immunity conferred by IG is only temporary. As a result, for nonimmune contacts aged 6-11 months, MMR PEP was preferentially recommended over IG PEP whenever MMR could be administered within 72 hours of initial exposure in order to provide protection for the duration of the outbreak. DOHMH subsequently contacted nonimmune contacts again after their incubation period to determine if rash developed; contacts who could not be reached after 3 attempts were assumed to have not developed measles. Contacts who developed rash were investigated to determine if they had measles.
Post-Exposure Prophylaxis Effectiveness Analysis
For the purpose of this analysis, all cases who subsequently developed measles were considered as contacts. All contacts, inclusive of those who developed measles, were then subject to the same exclusion criteria regardless of disease outcome. Contacts who were aged ≥19 years at the time of their exposure were excluded from the analysis because adults typically do not have copies of their immunization records and reporting of immunization doses to the CIR is only required for persons aged <19 years. As a result, we were unable to distinguish adults who were truly unvaccinated from those who were missing their immunization records. Contacts were also excluded from the analysis if they received 1 or more measles-containing vaccines prior to exposure, had a positive IgG titer, their age could not be determined, their immunization history could not be determined, or if the timing of measles PEP administration in relation to the time of exposure to measles could not be determined.
Measles PEP effectiveness was calculated as [(1 − RR) × 100%], where relative risk (RR) represents the risk of developing measles among contacts who received measles PEP compared to those who did not receive measles PEP. The 95% confidence limits (CIs) were constructed around the RR and converted using the effectiveness formula. Measles PEP effectiveness was calculated for MMR PEP alone, IG PEP alone, and for any measles PEP (ie, MMR PEP or IG PEP) combined. For the MMR PEP effectiveness analysis, contacts who received IG PEP or were aged <6 months at the time of exposure were further excluded to avoid bias due to IG PEP receipt or potential for disease protection through maternal antibodies. For the IG PEP effectiveness analysis, only contacts who received MMR PEP were excluded. Contacts who received either PEP beyond the respective ACIP recommended interval were included in analyses as not having received PEP.
RESULTS
NYC DOHMH identified a total of 3409 contacts, including 58 who developed measles. Of these, 709 (21%), including 9 who developed measles, were excluded due to age (≥19 years) at the time of exposure. Subsequently, 2314 (68%) were excluded due to prior receipt of 1 or more doses of measles-containing vaccine, 3 (<1%) were excluded due to prior positive IgG titers, 43 (1%) were excluded due to undetermined age, 21 (<1%) were excluded due to unknown vaccination history, and 1 contact who developed measles (<1%) was excluded due to uncertain timing of MMR PEP administration (Figure 1) . Table 1 shows the age distribution of the 318 nonimmune contacts who were included in the analysis stratified by type of measles PEP received. Of the contacts, 225 (71%) were contacted after their incubation period to determine if rash developed. Contacts occurred in all age groups; however, within each age group, the proportion of contacts who received PEP differed. Among the contacts, 121 (38%) received PEP, including 44 (14%) who received MMR PEP and 77 (24%) who received IG PEP administered intramuscularly at a dose of 0.5 mL/kg. All contacts who received IG PEP were aged <1 year. The remaining 197 (62%) contacts did not receive any PEP (n = 189) or received PEP within their incubation period but beyond the appropriate timeframe according to ACIP guidelines (n = 31 contacts who received MMR, at a median of 11 days after initial exposure; none developed measles). The large number of contacts who did not receive any PEP is attributed to the narrow window for administration; contacts identified and notified of their exposure to measles beyond the window for PEP were not recommended for PEP.
Among the 318 contacts included in the analysis, 48 (15%) developed measles, of which 1 contact was aged <6 months, 11 were 6 to <12 months, 19 were 1 to <5 years, and 17 were 5 to <19 years. Forty-six (23%) of the 197 contacts who did not receive any measles PEP developed measles (Table 2) . Two (4.5%) contacts who received MMR PEP developed measles. These contacts were aged 6 to <12 months; 1 met the clinical case definition and was confirmed to have wild-type measles infection through virus genotyping. The second had generalized maculopapular rash with respiratory symptoms, but genotyping was not performed, and vaccine-strain virus could not be ruled out as the cause of symptoms. The effectiveness for MMR PEP was 83.4% (95% CI, 34.4%, 95.8%). No contact who received IG PEP developed measles; the PEP effectiveness for IG was 100% (approximated 95% CI, 56.2%, 99.8%). Because zero cases of measles occurred among IG recipients, the 95% CI was approximated by adding a 0.5 adjustment to cell counts. The effectiveness of any measles PEP was 92.9% (95% CI, 71.4%, 98.3%). Effectiveness of any measles PEP remained significant, with a similar point estimate, when controlling for age <12 months vs >12 months, which was evaluated because of potential protection from maternal antibodies in infants aged <12 months (results not presented).
DISCUSSION
Measles PEP was highly effective in preventing measles in contacts aged <19 years during this outbreak. These findings support current ACIP recommendations for measles PEP. Given the brief window of time to administer measles PEP, these findings also highlight the importance of a rapid public health outbreak response to limit measles transmission. Timely administration of PEP can help to interrupt measles transmission and limit the size of an outbreak.
Although it is challenging to conduct an effectiveness evaluation in the context of a highly vaccinated population, this analysis has a number of advantages compared to prior PEP effectiveness studies. At the time of the outbreak, this had been the largest measles outbreak in the United States since measles elimination; the large number of cases and exposed contacts increased the power of the calculations. Complete immune status for all contacts included in the analysis was confirmed through rigorous ascertainment and review of immunization records and IgG titers. This enabled the PEP effectiveness analyses to be limited to contacts who were truly not immune at the time of their exposure, removing the potential for bias due to immune protection. Timing of PEP administration was also determined with confidence (ie, number of days from first exposure to receipt of PEP), allowing for PEP effectiveness to be assessed in the context of current ACIP guidelines and removing the potential for misclassification of receipt of PEP.
Limitations of this analysis mirror those from previous studies. We were unable to control for external factors such as duration and intensity of exposure to measles, which may differentially affect the risk of developing measles in different settings and among different age groups. This risk may also have changed throughout the course of the outbreak with more rapid isolation of infectious cases. This analysis resulted in a wide confidence interval for MMR PEP effectiveness due to the small number of secondary cases. The majority of IG PEP recipients were aged <6 months, which may have resulted in an overestimate of IG PEP effectiveness due to potential protection against measles from maternal antibodies. Furthermore, the effectiveness of PEP in adults, immunocompromised persons, and pregnant women was not assessed. The sample size was not large enough to control for the timing of prophylaxis administration within the recommended time interval, which may impact the effectiveness of PEP. Contacts who received measles prophylaxis beyond the recommended interval (n = 31 for MMR PEP, n = 0 for IG PEP) were considered as not having received prophylaxis. However, it is possible that prophylaxis after the recommended interval may confer some protection. To evaluate this limitation, sensitivity analyses were conducted wherein contacts who received prophylaxis beyond the recommended interval were considered as having received valid prophylaxis or were excluded from the analysis; results of these analyses were not statistically different from those presented. Inclusion of these individuals as not having received prophylaxis provides a more conservative estimate of PEP effectiveness. Sensitivity analyses were also conducted for the 1 contact who developed measles that was excluded due to uncertain timing of MMR PEP administration; results were not statistically different from those presented. Furthermore, although staff made rigorous attempts to follow-up with contacts after their incubation period was completed to confirm whether the contact developed measles, 93 (29%) could not be reached. These contacts were considered as not having developed measles given the low likelihood of disease in the absence of a provider report or diagnostic test result. Exclusion of these contacts did not produce results statistically different from those presented. Last, disease severity and contagiousness were not evaluated as part of the current analysis due to the limited number of individuals who developed measles after receiving PEP during this outbreak.
The effectiveness of receiving MMR or IG PEP was 93% during this outbreak. Independently, MMR PEP and IG PEP effectiveness were 83% and 100% respectively. Our findings are in line with those from other studies from Australia and Abbreviations: CI, confidence interval; IG, immune globulin; MMR, measles, mumps, and rubella; PEP, post-exposure prophylaxis. a A total of 110 contacts were excluded because they received IG PEP (N = 77) and/or were <6 months of age (N = 107).
b A total of 44 contacts were excluded because they received MMR PEP. The 95% CI was approximated by adding 0.5 to each cell. Spain, which demonstrated MMR PEP effectiveness at 100% and 90.5%, respectively [19, 20] . The slightly lower estimate of MMR PEP effectiveness in our analysis may be more conservative than that of other studies due to the exclusion of adult contacts, contacts who had received 1 dose of measles-containing vaccination prior to exposure, and contacts with unknown immune history. Several studies have shown IG PEP effectiveness ranging from 69% to 83% in preventing measles infection when given shortly after exposure to measles [9, 10, 19, 21, 22] . However, IG was not effective in preventing infection in one study [15] . The higher effectiveness of IG PEP in this evaluation may be due to the restriction of administration of IG to within 6 days of initial exposure. Additionally, the dosage of intramuscular IG (0.5 mL/kg) administered to contacts in this outbreak was higher than that used in previous studies and may have contributed to higher effectiveness due to a dose-response effect [26, 27] . In 2012, ACIP increased the recommended dose of intramuscular IG to 0.5 mL/kg due to lower concentrations of antibodies in IG in the post-vaccination era [2] . These findings indicate that timely administration of measles PEP is a highly effective control measure for preventing measles transmission. Future studies to evaluate the effect of timing of measles PEP administration on PEP effectiveness both within and beyond the recommended time interval are warranted. 
